All In Biotech

Drug Trial Radar · NCT04711226

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

An Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Adults With Type 1 Diabetes Undergoing Islet Cell Transplant

Last checked: Nov 19, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Feb 19, 2021

Primary completion

Jun 2024

Study completion Jun 2026

Sponsor

Lead sponsor
Anelixis Therapeutics, LLCIndustry
Sponsor type
Industry
First posted
Jan 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • AT-1501Drug

    AT-1501 IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety- Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)Time frame: Accessed from date of transplant through 1 year post transplant for approximately 2 years
  2. Efficacy- Insulin independenceTime frame: Days 75 , Day 365 post-first transplant, and final transplant and 1 year after discontinuation of AT-1501

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Alberta

    Edmonton, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.